Gear producers, hashish processors and drug builders can license CURE’s patented strategies for optimum extraction of cannabinoids
LOS ANGELES, April 21, 2020 (GLOBE NEWSWIRE) An progressive drug supply and growth firm, as we speak introduced the issuance of two U.S. Patents: No. 10,639,339 and 10,624,940. These patents signify an growth of CURE’s present “product by course of” patents for acquiring a number of distinctive hashish concentrates utilizing tremendous essential fluid extraction (SCFE). These embrace cannabinoid concentrates enriched in cannabidiol (CBD), tetrahydrocannabinol (THC) and cannabigerol (CBG), a non-psychoactive cannabinoid which has proven promising therapeutic exercise in animal research in areas comparable to inflammatory bowel illness, most cancers and infectious ailments.
“Including CBG to our SCFE patent portfolio aligns with the most recent analysis and early scientific proof supporting its therapeutic profit,” stated Rob Davidson, CEO of CURE Pharmaceutical. “We proceed to increase this portfolio to the most recent industrial functions for SCFE, offering our patent licensees and their prospects expanded IP rights.”
CURE is granting equipment manufacturers, hashish processing corporations and cannabinoid drug builders licenses to its portfolio of issued and pending course of and composition patents for isolating cannabinoids utilizing a sophisticated SCFE expertise using carbon dioxide because the solvent. Whereas the patents cowl the incorporation of hashish extracts into a number of dosage kinds, CURE has retained all rights to making use of these strategies in oral skinny movies.
The two patents cowl the extraction and purification of hashish plant materials, in addition to subsequent processing of hashish extracts for drug formulation. This extraction and fractioning of bioactive cannabinoid molecules permits for the mixing of those molecules into dosage types.
About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically built-in drug supply and improvement firm dedicated to bettering drug efficacy, security, and affected person expertise by way of its proprietary drug dosage varieties and supply programs. CURE has an FDA- and DEA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug supply platform. CUREform contains CUREfilm®, one of the crucial superior oral skinny movies in the marketplace at this time; microCURE™, an modern emulsion know-how using proprietary encapsulation strategies; and CUREpods™ a novel chewable supply system. CUREform’s mixed applied sciences present alternatives for each speedy and managed-launch drug supply of a variety of lively components. CURE companions with biotech, pharmaceutical, and wellness corporations worldwide and has positioned itself to advance quite a few therapeutic classes, together with the pharmaceutical hashish sector, with partnerships within the U.S, Canada, Israel, and different markets. The corporate’s mission is to enhance individuals’s lives by redefining how medicines are delivered and skilled.
This press launch comprises ahead–trying statements that contain dangers and uncertainties. There are essential components that might trigger precise outcomes to vary materially from these within the ahead–wanting statements. These components embrace, with out limitation, the power to efficiently market the partnered merchandise, the problem in predicting the timing or end result of associated analysis and improvement efforts, partnered product traits and indications, advertising and marketing approvals and launches of different merchandise, the influence of pharmaceutical business regulation, the influence of aggressive merchandise and pricing, the acceptance and demand of latest pharmaceutical merchandise, the influence of patents and different proprietary rights held by opponents and different third events and the power to acquire financing on favorable phrases. The ahead–trying statements on this press launch mirror the Firm’s judgment as of the date of this press launch. The Firm disclaims any intent or obligation to replace these ahead–trying statements. This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase nor shall there be any sale of our securities in any state or jurisdiction by which such provide, solicitation or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.